FENNEC PHARMACEUTICALS
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperat... ures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
FENNEC PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.fennecpharma.com
Total Employee:
1+
Status:
Active
Contact:
(919) 636-4530
Email Addresses:
[email protected]
Total Funding:
58.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Entos Pharmaceuticals
Entos Pharmaceuticals is a healthcare biotechnology company that develops nucleic acid therapies.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management investment in Post-IPO Equity - Fennec Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Convertible Note - Fennec Pharmaceuticals
Official Site Inspections
http://www.fennecpharma.com
- Host name: cloudproxy10107.sucuri.net
- IP address: 192.124.249.107
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Fennec Pharmaceuticals"
Investor Relations | Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. specializes in developing and commercializing PEDMARK® to reduce platinum-induced ototoxicity in pediatric cancer patients.See details»
Fennec Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (919) 636-4530 Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF …See details»
Fennec Pharmaceuticals (TSX:FRX) Company Profile & Description
Apr 17, 2025 Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a …See details»
FENC - Fennec Pharmaceuticals, Inc. | Company Profile | OTC …
Jan 31, 2025 www.fennecpharma.com (919) 636-4530. [email protected]. Business Description. ... He also served as the Managing Director at Accelera S.r.l., an independent …See details»
Fennec Pharma - Craft
Oct 28, 2024 Fennec Pharma has 5 employees at their 1 location and $21.25 m in annual revenue in FY 2023. See insights on Fennec Pharma including office locations, competitors, …See details»
Overview, News & Similar companies - ZoomInfo.com
View Fennec Pharmaceuticals (www.fennecpharma.com) location in North Carolina, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Fennec Pharmaceuticals Reports First Quarter 2025 Financial …
1 day ago ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and …See details»
Fennec Pharmaceuticals Inc - Company Profile - GlobalData
Website fennecpharma.com Telephone 1 919 6364530. No of Employees 36. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange FRX (TSE) Revenue (2023) …See details»
About Fennec Pharmaceuticals
Pharmaceuticals organization. • Work with/Partner with independent distributors and leverage their relationships/contacts to create new opportunity, expand reach, and improve access in …See details»
Fennec Pharmaceuticals Inc. (FRX.TO) - Yahoo Finance Canada
See the company profile for Fennec Pharmaceuticals Inc. (FRX.TO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter …
Mar 6, 2025 For more information, please visit www.fennecpharma.com. For further information, please contact: Investors: Robert Andrade Chief Financial Officer Fennec Pharmaceuticals …See details»
Fennec Pharmaceuticals Inc Management Team | Org Chart
Fennec Pharmaceuticals Inc employs 32 employees. The Fennec Pharmaceuticals Inc management team includes Jeff Hackman (Chief Executive Officer and Director), Christopher …See details»
Fennec Pharmaceuticals Inc | LinkedIn
Fennec Pharmaceuticals Inc | 4,951 followers on LinkedIn. Fiercely devoted to the fight against ototoxicity in pediatric cancer patients who receive cisplatin-based chemotherapy. | Fiercely ...See details»
H I R I N G N O W - fennecpharma.com
[email protected]. www.fennecpharma.com. N O W. H I R I N G. Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company. ... key stakeholders across the …See details»
Fennec Pharmaceuticals Inc Overview | SignalHire Company Profile
Fiercely dedicated to the fight against cisplatin-induced ototoxicity. www.fennecpharma.com. Fiercely dedicated to the fight against cisplatin-induced ototoxicity. www.fennecpharma.com ...See details»
Fennec Pharma - 2025 Company Profile & Funding - Tracxn
Apr 25, 2025 Fennec Pharma has raised funding over 11 rounds. Its first funding round was on Jun 2004. Its latest funding round was a Post IPO round on Sep 27, 2022 for $20M. 1 investor …See details»
Fennec Pharmaceuticals Announces Second Quarter 2022 …
Aug 12, 2022 We are focused on ensuring readiness for our PDUFA target action date of September 23, 2022, and have built out our commercial organization with key hires, including …See details»
Q1 2025 Fennec Pharmaceuticals Inc Earnings Call
1 day ago Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals' first-quarter 2025 earnings and corporate update conference call. (Operator Instructions) As a …See details»
Fennec Pharmaceuticals Reports First Quarter 2025 Financial
1 day ago A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. Financial Update . The selected financial data …See details»
Fennec Pharmaceuticals to Report First Quarter 2025
5 days ago To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please …See details»